By Cristina Gallardo
The U.S. drug regulator declared that the shortage of weight-loss medications Wegovy and Ozempic has been resolved, Danish pharma giant Novo Nordisk said.
The Food and Drug Administration's announcement confirms that the U.S. supply of these prescription-only drugs now meets or exceeds the current and projected demand in the country, the pharmaceutical company said Friday.
Novo Nordisk added that it continues to produce Wegovy and Ozempic around the clock, seven days a week, in order to meet the sky-rocketing demand.
"No one should have to compromise their health due to misinformation and reach for fake or illegitimate knock-off drugs that pose significant safety risks to patients," said Dave Moore, executive vice president for U.S. Operations at Novo Nordisk.
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
February 21, 2025 10:30 ET (15:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。